Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel
NCT ID: NCT01276275
Last Updated: 2016-03-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
7200 participants
OBSERVATIONAL
2014-01-31
2015-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A further purpose is to ascertain and estimate the crude incidence rate of bleeding, arrhythmias, heart failure, acute renal failure, acute liver failure, dyspnoea and gout among new users in the three cohorts of ticagrelor, clopidogrel and prasugrel.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome
NCT05183178
Ticagrelor Pharmacokinetics in NSTEMI
NCT02292277
Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG
NCT01755520
Ticagrelor and Peripheral Arterial Disease
NCT02407314
Antithrombotic Triple Therapy in Humans
NCT01812200
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exposure Group 1
First time users of ticagrelor
Risk of selected safety events
First time users of ticagrelor, clopidogrel and prasugrel, respectively
Exposure Group 2
First time users of clopidogrel
Risk of selected safety events
First time users of ticagrelor, clopidogrel and prasugrel, respectively
Exposure Group 3
First time users of prasugrel
Risk of selected safety events
First time users of ticagrelor, clopidogrel and prasugrel, respectively
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Risk of selected safety events
First time users of ticagrelor, clopidogrel and prasugrel, respectively
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Helle Kieler, MD, PhD, Assoc Prof
Role: PRINCIPAL_INVESTIGATOR
Centre for Pharmacoepidemiology, Karolinska Institute, Stockholm
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Stockholm, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D5130N00010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.